Local therapy for oligometastatic esophageal squamous cell carcinoma: a prospective, randomized, Phase II clinical trial
Qi Liu, Junqiang Chen, Baosheng Li, Jinjun Ye, Shihong Wei, Yaohui Wang, Huanjun Yang, Zhengfei Zhu, Songtao Lai, Ling Li, Yun Chen, Jialei Wang, Jiaqing Xiang, Kuaile Zhao, Qi Liu, Junqiang Chen, Baosheng Li, Jinjun Ye, Shihong Wei, Yaohui Wang, Huanjun Yang, Zhengfei Zhu, Songtao Lai, Ling Li, Yun Chen, Jialei Wang, Jiaqing Xiang, Kuaile Zhao
Abstract
For patients with oligometastatic esophageal squamous cell carcinoma, the efficacy of local therapy is still controversial because of patient selection and lack of adequate controls in most studies. Here the authors design the ESO-Shanghai 13 trial, a prospective, multicenter, randomized, Phase II trial, to assess the impact of combined local therapy and systemic therapy on progression and survival compared with systemic therapy alone for patients with four or less metastases. A total of 102 patients will be recruited over 3 years from approximately five centers and randomized in a 1:1 ratio to receive either systemic therapy alone or systemic therapy and local therapy, such as radiation, surgery and thermal ablation. The primary endpoint is progression-free survival. The secondary endpoints are overall survival, local control, toxicity and quality of life. Clinical trial registration: NCT03904927 (ClinicalTrials.gov).
Keywords: esophageal squamous cell carcinoma; local therapy; oligometastasis.
Source: PubMed